XENPOZYME is the first and only disease-specific treatment for non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adults and children.

XENPOZYME® (olipudase alfa-rpcp) is the first and only disease-specific treatment for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult …

XENPOZYME provides the enzyme that is deficient, helping to reduce the buildup of a substance called sphingomyelin in cells. XENPOZYME is not expected to impact symptoms related to the …

See XENPOZYME® (olipudase alfa-rpcp) dosing phases, dose escalation, maintenance, and pretreatment steps. See website for Important Safety Information & Full Prescribing …

Explore support resources and download forms & guides to support you in your XENPOZYME® (olipudase alfa-rpcp) treatment. See website for Important Safety Information & Full …

See XENPOZYME® (olipudase alfa-rpcp) dosing information and download the patient dosing guide here. See website for Important Safety Information & Full Prescribing Information, …

XENPOZYME® (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

XENPOZYME® (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Patients treated with XENPOZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including …

Download informative resources for prescribing XENPOZYME® (olipudase alfa-rpcp) to your patients. See website for Important Safety Information & Full Prescribing Information, Including …